Treatment of chronic viral hepatitis C in children and adolescents: UK experience
| Autor: | M Abdel-Hady, Eleanor Barnes, DA Kelly, Suzanne Davison, Paul Davies, Sanjay Bansal, Sarah Tizzard, S Mulla, Giorgina Mieli-Vergani, M Brown |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Genotype Antiviral Agents Polymorphism Single Nucleotide Polyethylene Glycols chemistry.chemical_compound Liver disease Quality of life Internal medicine Ribavirin Humans Medicine Chronic viral hepatitis C Child Retrospective Studies Dose Modification business.industry Interferon-alpha Hepatitis C Chronic Hepatology medicine.disease Hepatitis C Recombinant Proteins United Kingdom Surgery Treatment Outcome chemistry Tolerability Child Preschool Pediatrics Perinatology and Child Health Quality of Life RNA Viral Drug Therapy Combination Female business |
| Zdroj: | Archives of Disease in Childhood. 99:505-510 |
| ISSN: | 1468-2044 0003-9888 |
| DOI: | 10.1136/archdischild-2013-304601 |
| Popis: | Aim: To review the efficacy and tolerability of pegylated interferon-α and ribavirin for treatment of chronic hepatitis C (CHC) in children in the UK. Methods: Retrospective review of children treated for CHC in 3 UK paediatric specialist liver centres between 2005 and 2010. Data on viral response to treatment, demographic and clinical details were collected. Treatment outcome was assessed by the absence of detectable viral RNA in blood 24 weeks after treatment - sustained viral response (SVR). Results: 75 children were included; 34 genotype 1; 39 genotypes 2 and 3; 2 genotype 4. Overall SVR was achieved in 54/71 (76%); 65% genotype 1; 89% genotypes 2 and 3; 100% genotype 4. Early response at 12 weeks was achieved in 53 and sustained in 47 (89%). Data on rapid response after 4 weeks of treatment were available in 25; 17/25 (68%) responded and 16 of these (94%) achieved SVR. IL28 T/T genotype was associated with higher SVR. There were no significant changes in weight and height z scores from baseline compared with 24 weeks post-treatment followup. No child discontinued treatment due to side effects, although 43 required dose modification. Treatment affected quality of life (QoL) in the initial 12 weeks of treatment, which improved by the end of treatment. Conclusions: Children respond well to therapy for CHC. Treatment was tolerated with minimal impact on QoL and no signi ficant effect on growth. Knowledge of viral and IL28 genotypes and early viral response is useful to plan treatment in children and provide appropriate counselling. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|